Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In a population-based retrospective review of first-line treatment of metastatic renal cell carcinoma, sunitinib was shown to double overall survival when compared to interferon alpha.

Sunitinib Improves Overall Survival in Patients with Renal Cancer